FEBRUARY 2021 | ISSUE 107

# M&A AT A GLANCE

### **Key Takeaways**

- Coming off a strong December, M&A began 2021 down by most measures. In the U.S., total deal value and deal count were down 36% and 4%, respectively, with strategic deals accounting for a larger portion of the declines. Sponsor deals were more mixed, with a 14% decrease in deal value but a 15% increase in deal count. Globally, total deal value and deal count were similarly down 34% and 18%, respectively, again with strategic deals accounting for more of the slowdown than sponsor deals.
- ▶ U.S. cross-border activity declined both for inbound and outbound activity by dollar value (76% and 15%, respectively). The drop in inbound deal value was largely due to a return to more normal activity levels following AstraZeneca plc's \$40 billion acquisition of Alexion Pharmaceuticals, Inc. in December. Deal counts also decreased for inbound transactions by 19%, but increased by 2% for outbound transactions.
- ► Canada was the top country for U.S. inbound transactions by deal count both in January and over the last 12 months (LTM). Similarly, the U.K. was the target country of choice for U.S. outbound deals, maintaining its LTM position.
- Computer & Electronics remained the top industry by dollar value and deal count for January and LTM. Despite declining by 15% in deal value in January, the industry gained 5% in deal count over December.
- ▶ In January, there were 16 U.S. SPAC acquisitions announced (totaling \$36 billion in deal value), down 6% by deal count but up 42% by deal value over December. Globally, SPAC acquisitions were similarly mixed, with deal count down 10% but total value up 10%
- ▶ U.S. public merger highlights include the following:
  - $\circ~$  No U.S. public mergers in January used stock only as consideration, compared to 25% LTM. Instead, 44% of deals used a mix of cash and stock, compared to 11% of such deals LTM.
  - No deals involved a tender offer, compared to 25% LTM, and hostile/unsolicited offers declined to 10% of deals announced in January compared to 17% LTM
  - Unaffected premium percentages remained at similar levels to those seen in December, at 31% as compared to 40% LTM.
  - No deals had a go-shop compared to 9% LTM.

2.497 deals – ▼17.6%

\$181.9 billion – ▼42.3%

\$129.4 billion – ▼15.8%

406 deals – ▼1.2%

2,091 deals - ▼20.2%

Strategic

Sponsor

#### er Activity




### tivitx



All data is for January 2021 and is as of February 10, 2021 unless otherwise specified. Each metric in this publication that references deal volume by dollar value is calculated from the subset of the total number of deals that includes a disclosed deal value.


### M&A at a Glance

#### FEBRUARY 2021 | ISSUE 107




Deal Value (US\$B)


#### Most Active U.S. Target Industries<sup>1</sup>



#### Last 12 Months








### M&A at a Glance

#### FEBRUARY 2021 | ISSUE 107



#### Average Break Fees as % of Equity Value<sup>2</sup>

#### Average Break Fees as % of Equity Value<sup>3, 4</sup>


	January 2021	Last 12 Months
Target Break Fee for All Mergers	3.6	3.3


	January 2021	Last 12 Months
Reverse Break Fee for All Mergers⁵	5.5	5.3
Reverse Break Fee for Mergers Involving Financial Buyers <sup>6</sup>	6.0	6.1
Reverse Break Fee for Mergers Involving Strategic Buyers <sup>7</sup>	4.8	4.7

#### U.S. Public Merger Go-Shop Provisions<sup>4</sup>

	January 2021	Last 12 Months
% of Mergers with Go-Shops	0.0	8.5
% of Mergers Involving Financial Buyers with Go- Shops <sup>8</sup>	0.0	19.2
% of Mergers Involving Strategic Buyers with Go- Shops <sup>9</sup>	0.0	4.4
Avg. Go-Shop Window (in Days) for All Mergers with Go-Shops <sup>10</sup>	N/A	37.6
Avg. Go-Shop Window (in Days) for Mergers Involving Financial Buyers with Go-Shops <sup>11</sup>	N/A	36.0
Avg. Go-Shop Window (in Days) for Mergers Involving Strategic Buyers with Go-Shops <sup>12</sup>	N/A	40.3

### M&A at a Glance





#### Tender Offers as % of U.S. Public Mergers

January 2021	0.0
Last 12 Months	24.5

#### Hostile/Unsolicited Offers as % of U.S. Public Mergers<sup>14</sup>

January 2021	10.0
Last 12 Months	16.7

#### Unaffected Premium %<sup>15</sup>

January 2021	30.8
Last 12 Months	40.3


#### Total Target Adviser Fee(s) as % of Equity Value

January 2021	N/A
Last 12 Months	1.3

#### Inbound U.S. Crossborder Transactions for January 2021 Inbound U.S. Crossborder Transactions for the Last 12 Months Deal Value (US\$B) Deal Value (US\$B) Switzerland \$4.05 U.K. \$61.41 \$2.99 \$32.72 Singapore Canada \$2.83 Israel Japan \$29.46 Canada \$2.17 Germany \$28.25 U.K. \$1.61 France \$16.46 \$0 \$10 \$20 \$30 \$40 \$50 \$60 \$70 \$0 \$6 \$12 \$18 \$24 By Number of Deals By Number of Deals Canada 21 Canada 248 U.K. 165 U.K. 15 123 Japan France 52 China, France, Singapore & Sweden<sup>16</sup> 51 Germany 0 10 20 30 40 0 100 200 300 400


#### Top 5 Countries of Origin or Destination for Inbound U.S. Crossborder Transactions

Top 5 Countries of Origin or Destination for Outbound U.S. Crossborder Transactions






Deal Value (US\$B)




FEBRUARY 2021 | ISSUE 107

## Appendix: M&A Activity – 12 Month Trends





Global Deal Value (US\$B)




U.S. Number of Deals




#### FEBRUARY 2021 | ISSUE 107



Inbound U.S. Crossborder Transactions






----- By Number of Deals

By Deal Value (US\$B)

U.S. SPAC Acquisitions<sup>18, 19</sup>



#### Global Crossborder Transactions

### Endnotes

- 1. Industries categories are determined and named by Cortex.
- 2. Based on the highest target break fees and reverse break fees payable in a particular deal. Dashed lines indicate that there are no data points for the month of April 2020, as there were no applicable deals in April 2020.
- 3. There were nine transactions in January 2021.
- 4. Financial and strategic categories are determined by Deal Point Data.
- 5. Five transactions in January 2021 had a reverse break fee.
- 6. Three transactions in January 2021 involving a financial buyer had a reverse break fee.
- 7. Two transactions in January 2021 involving a strategic buyer had a reverse break fee.
- 8. Three transactions in January 2021 involved a financial buyer.
- 9. Six transactions in January 2021 involved a strategic buyer.
- 10. Zero transactions in January 2021 had a go-shop provision.
- 11. Zero transactions in January 2021 involving a financial buyer had a go-shop provision.
- 12. Zero transactions in January 2021 involving a strategic buyer had a go-shop provision.
- 13. Due to rounding, percentages may not add up to 100%.

- 14. This data includes both announced transactions for which a definitive merger agreement was reached and filed and those for which a definitive merger agreement was never reached and filed (including withdrawn transactions).
- 15. Unaffected Premium % indicates the difference between the current price per share offered as consideration in the transaction and the "unaffected price", reflected as a percentage. The "unaffected price" is the target's closing stock price on the date that is one calendar day prior to the first public disclosure regarding a potential deal involving the target and on which the target's stock price was unaffected by the news of the deal.
- 16. Each of China, France, Singapore and Sweden was the country of origin for five transactions in January 2021.
- 17. Each of Australia, Germany and the Netherlands was the country of destination for six transactions in January 2021.
- 18. This data includes all SPAC acquisitions for which a deal agreement has been announced.
- 19. This data reflects U.S. targets that have been acquired by a SPAC of any nationality. Dashed lines indicate that there were no applicable deals in April 2020 with a U.S. target.
- 20. This data reflects both U.S. and non-U.S. targets that have been acquired by a SPAC of any nationality.

The charts on p. 1–2 and 5–10 were compiled using Cortex, and are for the broader M&A market, including public and private transactions of any value. Deal volume by dollar value and average value of deals are calculated from the subset of deals that include a disclosed deal value. The charts on p. 3–4 were compiled using Deal Point Data, and include acquisitions seeking majority or higher control of U.S. targets valued at \$100 million or higher announced during the period indicated and for which a definitive merger agreement was reached and filed (except with respect to data regarding premiums and hostile/unsolicited offers, which is for all announced deals). "Last 12 Months" data is for the period from February 2020 to January 2021 inclusive. Data obtained from Cortex and Deal Point Data has not been reviewed for accuracy by Paul, Weiss.

### **Our Mergers & Acquisitions Practice**

Paul, Weiss is a leading law firm serving the largest publicly and privately held corporations and financial institutions in the United States and throughout the world. Our firm is widely recognized for achieving an unparalleled record of success for our clients, both in their bet-the-company litigations and their most critical strategic transactions. We are keenly aware of the extraordinary challenges and opportunities facing national and global economies and are committed to serving our clients' short- and long-term goals.

The Paul, Weiss M&A Group consists of more than 35 partners and over 125 counsel and associates based in New York, Washington, Wilmington, London, Toronto, Tokyo, Hong Kong and Beijing. The firm's Corporate Department consists of more than 60 partners and over 300 counsel and associates.

Our M&A Group is among the most experienced and active in the world. We represent publicly traded and privately held companies, leading private equity firms, financial advisors, and other financial institutions and investors in their most important mergers and acquisitions, joint ventures and other strategic transactions. Our expertise advising corporations and private investors in a broad range of sophisticated transactions enables us to identify new opportunities for our clients to realize value. We have particular experience in guiding clients as they engage in proxy battles, company-altering and market consolidating transactions or capital markets transactions.

Recent highlights include advising: Perspecta Inc. in its \$7.1 billion sale to Peraton and Veritas Capital; Inspire Brands in its \$11.3 billion acquisition of Dunkin' Brands Group; Cenovus Energy in its Cdn. \$23.6 billion combination with Husky Energy; The Kraft Heinz Company in the proposed \$3.2 billion sale of its cheese business to Groupe Lactalis; an affiliate of Roark Capital Group in its approximately \$1.5 billion acquisition of the ServiceMaster Brands businesses of ServiceMaster Global Holdings: Teladoc Health in its \$18.5 billion acquisition of Livongo Health; Chevron in its \$13 billion acquisition of Noble Energy: National General Holdings in its \$4 billion sale to The Allstate Corporation; affiliates of Roark Capital in its \$200 million investment in The Cheesecake Factory; General Atlantic, as lead investor in a consortium, in its \$8.7 billion acquisition of 58.com; The Medicines Company in its \$9.7 billion sale to Novartis; the Special Committee of the Board of Directors of Pattern Energy Group in its approximately \$6.1 billion sale to Canada Pension Plan Investment Board; Aptiv in its \$4 billion autonomous driving joint venture with Hyundai Motor Group; the Special Committee of the Board of Directors of CBS Corp. in its merger with Viacom to form ViacomCBS, a combined company with an enterprise value of more than \$40 billion; Elanco Animal Health in its \$7.6 billion acquisition of the animal health business of Bayer AG; funds managed by affiliates of Apollo Global Management in their \$2.7 billion acquisition of Shutterfly; the Independent Directors of Avon in its \$3.7 billion sale to Natura & Co.; KPS Capital Partners in its \$1.8 billion acquisition of Howden from Colfax; Trane Technologies in the \$15 billion Reverse Morris Trust spin-off and merger of its industrial business with Gardner Denver Holdings; Chevron in its proposed \$50 billion acquisition of Anadarko Petroleum; General Electric in the \$21.4 billion sale of its BioPharma business to Danaher Corporation: Encana Corp. (now known as Ovintiv) in its \$7.7 billion acquisition of Newfield Exploration Company; IBM in its \$34 billion acquisition of Red Hat; the Board of Directors of Harris Corporation in its \$37 billion merger of equals with L3 Technologies to form L3Harris Technologies; CSRA in its \$9.7 billion sale to General Dynamics; Bioverativ in its \$11.6 billion sale to Sanofi; ADP in its successful proxy contest against Pershing Square; and Agrium in its \$36 billion merger of equals with Potash Corp. of Saskatchewan.

This publication is not intended to provide legal advice, and no legal or business decision should be based on its content. Questions concerning issues addressed in this memorandum should be directed to:

Matthew W. Abbott +1-212-373-3402 Email

Jeffrey D. Marell +1-212-373-3105 Email Scott A. Barshay +1-212-373-3040 Email Robert B. Schumer +1-212-373-3097 Email Angelo Bonvino +1-212-373-3570 Email

Taurie M. Zeitzer +1-212-373-3353 Email Ariel J. Deckelbaum +1-212-373-3546 Email

Counsel Frances F. Mi, associates Feiran Felicia Chen, Stacy Hwang, Allyson N. Kaleita, Eliana Wasser and Ceecee Q. Yao, law clerks Joseph Krmpotich and Evan Yoo, and staff attorney Akiva Reich contributed to this publication.

### **Our M&A Partners**

Matthew W. Abbott	<u>Neil Goldman</u>	Kenneth M. Schneider	<u>Jeremy M. Veit</u>
Edward T. Ackerman	Bruce A. Gutenplan	Robert B. Schumer	Michael Vogel
<u>Scott A. Barshay</u>	David K. Lakhdhir	John M. Scott	<u>Ramy J. Wahbeh</u>
Angelo Bonvino	Brian C. Lavin	<u>Brian Scrivani</u>	<u>Steven J. Williams</u>
Ellen N. Ching	<u>Xiaoyu Greg Liu</u>	Kyle T. Seifried	Adam Wollstein
Rachael G. Coffey	Jeffrey D. Marell	<u>Cullen L. Sinclair</u>	<u>Betty Yap</u>
Ariel J. Deckelbaum	<u>Alvaro Membrillera</u>	Sarah Stasny	<u>Kaye N. Yoshino</u>
Ross A. Fieldston	Judie Ng Shortell	Tarun M. Stewart	<u>Tong Yu</u>
Brian P. Finnegan	<u>Carl L. Reisner</u>	<u>Laura C. Turano</u>	<u>Taurie M. Zeitzer</u>
Adam M. Givertz	Justin Rosenberg	Krishna Veeraraghavan	

© 2021 Paul, Weiss, Rifkind, Wharton & Garrison LLP. In some jurisdictions, this publication may be considered attorney advertising. Past representations are no guarantee of future outcomes.